The antiinfective medicine market in Canada experienced significant fluctuations from 2013 to 2023, with peak sales in 2015 at 2.45 billion CAD and a noticeable drop to 1.98 billion CAD in 2020, partially due to market dynamics and pandemic impacts. By 2023, sales modestly increased to 2.08 billion CAD, reflecting a slow recovery. Year-on-year variations have been volatile, with a noted significant increase in 2015 and downturns in 2016 and 2020. Overall, the recent five-year CAGR stands at -3.1%, indicating a contracting market over the past few years.
The forecast suggests a stabilization with modest growth, projecting a five-year CAGR of 0.51% through 2028, reaching anticipated sales of 2.15 billion CAD. Trends indicate the market is recovering slowly and heading towards a phase of gradual growth.
Future Trends to Watch For:
- The impact of new drug developments and approvals on market dynamics.
- Changes in infection patterns and healthcare policies influencing demand.
- The role of generic medications in market competition.
- Potential disruptions from global health events or supply chain challenges.
